Halozyme Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2016; filed August 9, 2016. Halozyme is a biotechnology company developing oncology therapies and licensing its ENHANZE rHuPH20 technology. Financial statements are unaudited.
Financial performance
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Total revenue | $33.3 million | $43.4 million | $75.8 million | $62.1 million |
| Operating income (loss) | ($21.7 million) | $4.2 million | ($37.9 million) | ($9.7 million) |
| Net income (loss) | ($26.9 million) | $3.0 million | ($46.7 million) | ($12.1 million) |
| Net loss per share | ($0.21) | $0.02 | ($0.37) | ($0.10) |
| Operating cash flow | Not separately stated for quarter | Not separately stated for quarter | ($25.9 million) | ($4.9 million) |
- Q2 revenue declined 23% year over year, chiefly because Q2 2015 included a $23.0 million AbbVie upfront license fee. Six-month revenue increased 22%.
- Q2 product sales were $13.7 million, royalties $12.3 million, and collaboration revenue $7.4 million. Six-month royalties rose to $23.7 million from $13.2 million, primarily reflecting higher Roche Herceptin SC sales.
- Research and development expense rose to $35.5 million in Q2 and $75.6 million for the half year, largely from increased PEGPH20 clinical activity and ENHANZE-related manufacturing costs. Management expects R&D spending to increase as development advances.
- Interest expense increased to $5.2 million in Q2 and $9.1 million for the half year, primarily due to the January royalty-backed loan. The filing does not report an overall gross margin; product sales less cost of product sales were $5.4 million for Q2 and $10.6 million for the half year.
Balance sheet, debt and liquidity
- At June 30, cash and cash equivalents were $61.2 million and available-for-sale marketable securities were $168.8 million, or $230.0 million combined. Total assets were $296.1 million; stockholders’ equity was $9.9 million.
- Reported debt carrying value was approximately $208.1 million, including $3.3 million current and $204.9 million long-term debt. The royalty-backed loan balance was $153.8 million and the Oxford/SVB term loan balance was $54.4 million.
- Six-month cash used in operations was $25.9 million. Investing activities used $106.1 million, mainly because of purchases of marketable securities; financing provided $149.9 million, including the new borrowing and refinancing activity.
- Management said available cash, cash equivalents and marketable securities should fund operations for at least 12 months, and projected year-end 2016 cash and cash equivalents of $170 million to $190 million. The projection depends on clinical and preclinical spending, manufacturing scale-up, milestones and royalties.
Material developments, outlook and risks
- In January 2016, Halozyme obtained a $150 million royalty-backed loan secured by Roche and Baxalta ENHANZE royalties. It bears interest at 8.75% plus LIBOR (9.45% at quarter-end); interest not paid may be added to principal. Management estimated repayment in Q1 2020, subject to royalty performance.
- In June 2016, the company refinanced its prior Oxford/SVB debt with a $55 million senior secured loan at 8.25%, including 18 months of interest-only payments and maturity in January 2021. It may draw another $15 million in 2017. Both loan facilities carry covenants; the company reported compliance at quarter-end.
- PEGPH20 was in Phase 2 and Phase 3 testing for stage IV pancreatic cancer. In the Stage 1 high-HA subgroup of the Phase 2 study, reported median progression-free survival was 9.2 months with PEGPH20 plus chemotherapy versus 6.0 months with chemotherapy alone; the filing notes limitations and exploratory analyses. A Phase 3 trial began in March 2016.
- Thromboembolic events prompted a 2014 clinical hold and revised protocols. The filing says these events remain under monitoring and that the Phase 2 study could be halted again for safety concerns. Regulatory approval and commercial success remain uncertain.
- After quarter-end, Halozyme resumed enrollment in its PEGPH20/Keytruda study under a revised protocol, started a PEGPH20/eribulin breast-cancer study with Eisai, and decided in August 2016 to discontinue the PRIMAL PEGPH20/docetaxel lung-cancer study.
- Key risks include continued operating losses, need for future financing, clinical and regulatory uncertainty, safety signals, dependence on collaborators and contract manufacturers, and debt-service obligations. The company reported no material legal proceedings and said disclosure controls were effective.
Important facts for investors to verify
- Whether royalty growth from Roche and Baxalta continues, and whether collaborator product launches and sales meet expectations.
- Upcoming PEGPH20 clinical results, especially mature Phase 2 data, Phase 3 progress, and thromboembolic safety findings.
- Actual cash burn versus management’s year-end cash projection, including the impact of clinical spending and manufacturing scale-up.
- Debt repayment assumptions, interest accumulation, covenant compliance, and the availability and terms of the optional $15 million draw.
- Whether collaboration and milestone revenue can offset rising R&D expense and support a path toward profitability.